A Curated Platform of Equity & Options Market Intelligence
Select Page

IMVT

Search by
TICKER SYMBOL

Immunovant Inc

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

28.95

0.56

(1.973%)

Volume:

739,083

52 week range:

18.16 - 45.58

Market Cap:

4.206B

Company Description:

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.